Industry Payments to Physicians for Opioid Products, 2013-2015.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Publication Year:
      2017
    • Subject Terms:
    • Subject Terms:
    • NAICS/Industry Codes:
      NAICS/Industry Codes 541613 Marketing Consulting Services
      325410 Pharmaceutical and medicine manufacturing
      414510 Pharmaceuticals and pharmacy supplies merchant wholesalers
      424210 Drugs and Druggists' Sundries Merchant Wholesalers
      325412 Pharmaceutical Preparation Manufacturing
      621110 Offices of physicians
      621111 Offices of Physicians (except Mental Health Specialists)
      923130 Administration of Human Resource Programs (except Education, Public Health, and Veterans' Affairs Programs)
    • Abstract:
      Objectives. To identify payments that involved opioid products from the pharmaceutical industry to physicians. Methods. We used the Open Payments program database from the Centers for Medicare and Medicaid Services to identify payments involving an opioid to physicians between August 2013 and December 2015. We used medians, interquartile ranges, and ranges as a result of heavily skewed distributions to examine payments according to opioid product, abuse-deterrent formulation, nature of payment, state, and physician specialty. Results. During the study, 375 266 nonresearch opioid-related payments were made to 68 177 physicians, totaling $46 158 388. The top 1% of physicians received 82.5% of total payments in dollars. Abuse-deterrent formulations constituted 20.3% of total payments, and buprenorphine marketed for addiction treatment constituted 9.9%. Most payments were for speaking fees or honoraria (63.2% of all dollars), whereas food and beverage payments were the most frequent (93.9% of all payments). Physicians specializing in anesthesiology received the most in total annual payments (median = $50; interquartile range = $16-$151). Conclusions. Approximately 1 in 12 US physicians received a payment involving an opioid during the 29-month study. These findings should prompt an examination of industry influences on opioid prescribing. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of American Journal of Public Health is the property of American Public Health Association and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
    • ISSN:
      00900036
    • Accession Number:
      124558341
  • Citations
    • ABNT:
      HADLAND, S. E.; KRIEGER, M. S.; MARSHALL, B. D. L. Industry Payments to Physicians for Opioid Products, 2013-2015. American Journal of Public Health, [s. l.], v. 107, n. 9, p. 1493, 2017. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=124558341. Acesso em: 17 fev. 2020.
    • AMA:
      Hadland SE, Krieger MS, Marshall BDL. Industry Payments to Physicians for Opioid Products, 2013-2015. American Journal of Public Health. 2017;107(9):1493. http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=124558341. Accessed February 17, 2020.
    • APA:
      Hadland, S. E., Krieger, M. S., & Marshall, B. D. L. (2017). Industry Payments to Physicians for Opioid Products, 2013-2015. American Journal of Public Health, 107(9), 1493.
    • Chicago/Turabian: Author-Date:
      Hadland, Scott E., Maxwell S. Krieger, and Brandon D. L. Marshall. 2017. “Industry Payments to Physicians for Opioid Products, 2013-2015.” American Journal of Public Health 107 (9): 1493. http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=124558341.
    • Harvard:
      Hadland, S. E., Krieger, M. S. and Marshall, B. D. L. (2017) ‘Industry Payments to Physicians for Opioid Products, 2013-2015’, American Journal of Public Health, 107(9), p. 1493. Available at: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=124558341 (Accessed: 17 February 2020).
    • Harvard: Australian:
      Hadland, SE, Krieger, MS & Marshall, BDL 2017, ‘Industry Payments to Physicians for Opioid Products, 2013-2015’, American Journal of Public Health, vol. 107, no. 9, p. 1493, viewed 17 February 2020, .
    • MLA:
      Hadland, Scott E., et al. “Industry Payments to Physicians for Opioid Products, 2013-2015.” American Journal of Public Health, vol. 107, no. 9, Sept. 2017, p. 1493. EBSCOhost, search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=124558341.
    • Chicago/Turabian: Humanities:
      Hadland, Scott E., Maxwell S. Krieger, and Brandon D. L. Marshall. “Industry Payments to Physicians for Opioid Products, 2013-2015.” American Journal of Public Health 107, no. 9 (September 2017): 1493. http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=124558341.
    • Vancouver/ICMJE:
      Hadland SE, Krieger MS, Marshall BDL. Industry Payments to Physicians for Opioid Products, 2013-2015. American Journal of Public Health [Internet]. 2017 Sep [cited 2020 Feb 17];107(9):1493. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=124558341